Conserv Bioscience News Today

Investegate announcements from hVIVO PLC, Imutex Phase I data published

/PRNewswire/ -- ConserV Bioscience Limited ("ConserV"), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and...

/PRNewswire/ -- ConserV Bioscience Limited ("ConserV"), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and...

Goodbye, 2021 -- the strange year when we tentatively rejoined the world, cautiously stepping out from our quarantining and still wearing masks. Hopefully as we look back at January to June 2021, we see progress made in our cities...

The use of mRNA vaccines to tackle Covid-19 marks the start of a new era of medicine

Using mRNA technology to develop vaccines for HIV and beyond ConserV Bioscience and eTheRNA immunotherapies are to collaborate on development of mRNA vaccines for infectious diseases. The initial focus of their alliance will be on the development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development. An effective vaccine to prevent HIV infe...

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases News provided by Share this article LONDON and NIEL, Belgium, March 4, 2021 /PRNewswire/ -- ConserV Bioscience Limited ("ConserV"), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA immunotherapies NV ("eTheRNA"), a clinical-stage immunotherapy company focused on mRNA antigen deliver...

ConserV Bio partners with eTheRNA on mRNA vaccine development 4th March 2021 London, UK-based ConserV Bioscience has teamed up with eTheRNA immunotherapies to develop mRNA-based vaccines for infectious diseases. The collaboration will combine ConserV’s expertise in identifying broadly protective antigens and eTheRNA’s TriMix immunostimulatory mRNA technology and novel lipid nanoparticle encapsulation technologies. The partnership will initially focus on the development and evaluation of mRN...

Bay Area researchers developing COVID vaccine to protect against future variants KTVUs Tom Vacar reports. LIVERMORE, Calif. - A Bay Area laboratory is helping come up with the technology that could make worldwide pandemics far easier and quicker to defeat.  The Lawrence Livermore National Laboratory, which assures the safety, security, and reliability of Americas nuclear weapons, is working to develop a vaccine to protect against future mutations. Lawrence Livermore National Laboratory (LLNL) ...

Lawrence Livermore National Laboratory announced this week a new collaboration with a United Kingdom company to develop a broad-spectrum or "universal" coronavirus vaccine.